Under 5 (Warnings and Precautions) in Afrezza's FDA approved Label, under 5.5 - Lung Cancer, it states:
"In clinical trials, two cases of lung cancer, one in controlled trials and one in uncontrolled trials (2 cases in 2,750 patient-years of exposure), were observed in participants exposed to AFREZZA while no cases were observed in comparators (0 cases in 2,169 patient -years of exposure). In both cases, a prior history of heavy tobacco use
was identified as a risk factor for lung cancer. Two additional cases of lung cancer (squamous cell) occurred in non-smokers exposed to AFREZZA and were reported by investigators after trial completion. These data are
insufficient to determine whether AFREZZA has an effect on lung cancer or respiratory tract tumors. In patients with active lung cancer, or in patients at risk for lung cancer, consider whether the benefits of AFREZZA use outweigh potential risk."
FYI.